… of 5963 heart transplantation patients found that the coronary … The mTOR sirolimus and
everolimus hinder vascular smooth … and survival in de novo cardiac transplantation. Transplant …

… and have been shown to prevent CAV or slow its progression in … of rapamycin antagonist
or mammalian target of rapamycin … heart transplant recipient evaluated the effects of de novo …

… as transplant coronary artery disease or cardiac transplant vasculopathy. … sirolimus in de
novo HT recipients would prevent coronary artery disease (CAD) and reduce acute rejection. …

… action effectively reduced allograft rejection and improved … Biopsy-proven acute rejection
occurred at similar frequency in … hypertension as key elements to prevent CKD. The analysis of …

… crossmatch may prevent hyperacute rejection in these … to sirolimus (but in general better
tolerated than sirolimus) … week post heart transplant to assess for de novo DSA or acute rise in …

… inhibitor of the mechanistic target of rapamycin (mTORI) in a … ii) de novo HTx patients with
renal insufficiency, (iii) patients who … the finding that T regs can prevent transplant rejection [12]. …

… to prevent donor organ loss to rejection following heart … transplant recipients, with a similar
drug exposure and lower total … another interventional trial or taking rapamycin or cyclosporine. …

… stents for delaying coronary artery restenosis [5,6]. Among HT … significantly decreased risk
of overall de novo malignancies post… A total of 12 of the 187 patients developed acute rejection …

… Moreover, mammalian target of rapamycin (mTOR) inhibitors are immunosuppressants that
… the potential to reduce intimal hyperplasia in the coronary arteries, thereby preventing CAV …

… Both sirolimus and everolimus reduce the incidence of acute … trial of 115 de novo heart
transplant recipients, the use of … by reducing the risk associated with coronary angiography and …